Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William D Figg

Showing results (1-10 of 635) with videos related to

Pageof 64
Sort By:
Cancer Biology & Therapy|November 26, 2010
Cabazitaxel: filling one of the gaps in the treatment of prostate cancerWilliam D Figg, William D Figg
Cancer Biology & Therapy|August 16, 2012
How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancerWilliam D Figg
The Lancet. Oncology|June 13, 2018
Antineoplastons: when is enough enough?William D Figg
Clinical Pharmacology and Therapeutics|January 18, 2006
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancerWilliam D Figg
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|December 11, 2024
Requests to Be a Content Expert Reviewer for Journals I Am Not Affiliated With: A Major, Ongoing Problem for the Academic CommunityWilliam D Figg
Cancer Biology & Therapy|September 21, 2007
Androgen receptor modulation: lessons learned from beyond the prostateNima Sharifi, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Identifying sources of interindividual pharmacokinetic variability with population modelingAlex Sparreboom, William D Figg
Cancer Biology & Therapy|February 2, 2016
Resisting resistance: Establishing new treatment options for CRPC patientsShaunna Beedie, William D Figg
The Lancet. Oncology|August 23, 2015
Epigenetic approaches to overcoming chemotherapy resistanceJulius Strauss, William D Figg
Cancer Biology & Therapy|May 12, 2004
Histone deacetylase inhibitors are potent radiation protectantsLuca Paoluzzi, William D Figg
Pageof 64

Showing results (1-10 of 635) with videos related to

Sort By:
Pageof 64
Cancer Biology & Therapy|November 26, 2010
Cabazitaxel: filling one of the gaps in the treatment of prostate cancerWilliam D Figg, William D Figg
Cancer Biology & Therapy|August 16, 2012
How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancerWilliam D Figg
The Lancet. Oncology|June 13, 2018
Antineoplastons: when is enough enough?William D Figg
Clinical Pharmacology and Therapeutics|January 18, 2006
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancerWilliam D Figg
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|December 11, 2024
Requests to Be a Content Expert Reviewer for Journals I Am Not Affiliated With: A Major, Ongoing Problem for the Academic CommunityWilliam D Figg
Cancer Biology & Therapy|September 21, 2007
Androgen receptor modulation: lessons learned from beyond the prostateNima Sharifi, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Identifying sources of interindividual pharmacokinetic variability with population modelingAlex Sparreboom, William D Figg
Cancer Biology & Therapy|February 2, 2016
Resisting resistance: Establishing new treatment options for CRPC patientsShaunna Beedie, William D Figg
The Lancet. Oncology|August 23, 2015
Epigenetic approaches to overcoming chemotherapy resistanceJulius Strauss, William D Figg
Cancer Biology & Therapy|May 12, 2004
Histone deacetylase inhibitors are potent radiation protectantsLuca Paoluzzi, William D Figg
Pageof 64